Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Jennifer L. Crombie(Dana-Farber Cancer Institute), Marcelo C. Pasquini(Cleveland Clinic), Fei‐Fei Liu(Jiangsu Hengrui Medicine (China)), Allison Winter(Cleveland Clinic), Stefan K. Barta(University of Pennsylvania), Brian Hess(Washington University in St. Louis), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sagar S. Patel(University of Utah), Tamara K. Moyo(Carolinas Medical Center), David Bernasconi(Bristol-Myers Squibb (United States)), Iris Isufi(Yale University), Bradley D. Hunter(Intermountain Healthcare), Amani Kitali(Bristol-Myers Squibb (United States)), Charalambos Andreadis(University of California, San Francisco), Natalie S. Grover(University of North Carolina at Chapel Hill), Priyanka A. Pophali(University of Wisconsin–Madison), Maria Lia Palomba(Memorial Sloan Kettering Cancer Center), Charimar Santiago Parrilla(Medical College of Wisconsin), Mecide Gharibo(Bristol-Myers Squibb (United States)), M. Frigault(Massachusetts General Hospital), Michael D. Jain(Moffitt Cancer Center)
Cited by 17
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664